Related references
Note: Only part of the references are listed.Lipid Effects of Psychiatric Medications
Junzo Watanabe et al.
CURRENT ATHEROSCLEROSIS REPORTS (2013)
Clozapine-Induced Mitochondria Alterations and Inflammation in Brain and Insulin-Responsive Cells
Veronica Contreras-Shannon et al.
PLOS ONE (2013)
A reversed-phase capillary ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) method for comprehensive top-down/bottom-up lipid profiling
Xiaoli Gao et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2012)
Genetic Data Supporting the NMDA Glutamate Receptor Hypothesis for Schizophrenia
Thomas L. Schwartz et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Excessive Insulin Secretion in Japanese Schizophrenic Patients Treated With Antipsychotics Despite Normal Fasting Glucose Levels
Takuro Sugai et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2012)
Obesity and adipokines: effects on sympathetic overactivity
Michael M. Smith et al.
JOURNAL OF PHYSIOLOGY-LONDON (2012)
Metabolomic Analysis of Biochemical Changes in the Plasma and Urine of First-Episode Neuroleptic-Naive Schizophrenia Patients after Treatment with Risperidone
Hua-Lin Cai et al.
JOURNAL OF PROTEOME RESEARCH (2012)
Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome
Wouter Beumer et al.
PSYCHONEUROENDOCRINOLOGY (2012)
Increased Levels of Kynurenine and Kynurenic Acid in the CSF of Patients With Schizophrenia
Klas R. Linderholm et al.
SCHIZOPHRENIA BULLETIN (2012)
Neural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment
E. Stip et al.
TRANSLATIONAL PSYCHIATRY (2012)
Perturbation in Mitochondrial Network Dynamics and in Complex I Dependent Cellular Respiration in Schizophrenia
Marina Rosenfeld et al.
BIOLOGICAL PSYCHIATRY (2011)
Association of serum levels of leptin, ghrelin, and adiponectin in schizophrenic patients and healthy controls
Meng-Chang Tsai et al.
INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE (2011)
Targeting Acyl-CoA:Diacylglycerol Acyltransferase 1 (DGAT1) with Small Molecule Inhibitors for the Treatment of Metabolic Diseases
Jingsong Cao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Metabolomic Profiling to Identify Potential Serum Biomarkers for Schizophrenia and Risperidone Action
Jiekun Xuan et al.
JOURNAL OF PROTEOME RESEARCH (2011)
Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism
Karen L. Teff et al.
PHYSIOLOGY & BEHAVIOR (2011)
Impaired Kynurenine Pathway Metabolism in The Prefrontal Cortex of Individuals With Schizophrenia
Korrapati V. Sathyasaikumar et al.
SCHIZOPHRENIA BULLETIN (2011)
Targeting glutamate synapses in schizophrenia
Julie R. Field et al.
TRENDS IN MOLECULAR MEDICINE (2011)
A Longitudinal Study on the Impact of Antipsychotic Treatment on Serum Leptin in Schizophrenia
Ganesan Venkatasubramanian et al.
CLINICAL NEUROPHARMACOLOGY (2010)
Clozapine Treatment Causes Oxidation of Proteins Involved in Energy Metabolism in Lymphoblastoid Cells: A Possible Mechanism for Antipsychotic-Induced Metabolic Alterations
Muhammad R. Baig et al.
JOURNAL OF PSYCHIATRIC PRACTICE (2010)
The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine
Chih-Chiang Chiu et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2010)
A Comparative Proteomics Analysis of Rat Mitochondria from the Cerebral Cortex and Hippocampus in Response to Antipsychotic Medications
Baohu Ji et al.
JOURNAL OF PROTEOME RESEARCH (2009)
Effects of Six Second Generation Antipsychotics on Body Weight and Metabolism - Risk Assessment and Results from a Prospective Study
A. Tschoner et al.
PHARMACOPSYCHIATRY (2009)
Clozapine causes oxidation of proteins involved in energy metabolism: a possible mechanism for antipsychotic-induced metabolic alterations
Consuelo Walss-Bass et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2008)
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor
Gang Zhao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Leptin and Ghrelin Levels in Patients With Schizophrenia During Different Antipsychotics Treatment: A Review
Othman Sentissi et al.
SCHIZOPHRENIA BULLETIN (2008)
Effect of antipsychotics on succinate dehydrogenase and cytochrome oxidase activities in rat brain
Emilio L. Streck et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2007)
Metabolomic mapping of atypical antipsychotic effects in schizophrenia
R. Kaddurah-Daouk et al.
MOLECULAR PSYCHIATRY (2007)
Neuroleptic treatment effect on mitochondrial electron transport chain -: Peripheral blood mononuclear cells analysis in psychotic patients
Jordi Casademont et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2007)
Medication-induced weight gain and dyslipidemia in patients with schizophrenia
Wayne S. Fenton et al.
AMERICAN JOURNAL OF PSYCHIATRY (2006)
Metabolic syndrome - a new world-wide definition. A consensus statement from the international diabetes federation
KGMM Alberti et al.
DIABETIC MEDICINE (2006)
Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia
LK Nilsson et al.
SCHIZOPHRENIA RESEARCH (2005)
Effects of antipsychotics on fat deposition and changes in leptin and insulin levels - Magnetic resonance imaging study of previously untreated people with schizophrenia
ZJ Zhang et al.
BRITISH JOURNAL OF PSYCHIATRY (2004)
Concerted elevation of acyl-coenzyme A:diacylglycerol acyltransferase (DGAT) activity through independent stimulation of mRNA expression of DGAT1 and DGAT2 by carbohydrate and insulin
RL Meegalla et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2002)
Increased cortical kynurenate content in schizophrenia
R Schwarcz et al.
BIOLOGICAL PSYCHIATRY (2001)
Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
JI Cleeman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Share Paper
